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ABSTRACT
It is essential to reveal the associations between var-
ious omics data for a comprehensive understanding
of the altered biological process in human wellness
and disease. To date, very few studies have focused
on collecting and exhibiting multi-omics associa-
tions in a single database. Here, we present iNetMod-
els, an interactive database and visualization plat-
form of Multi-Omics Biological Networks (MOBNs).
This platform describes the associations between
the clinical chemistry, anthropometric parameters,
plasma proteomics, plasma metabolomics, as well
as metagenomics for oral and gut microbiome ob-
tained from the same individuals. Moreover, iNet-
Models includes tissue- and cancer-specific Gene
Co-expression Networks (GCNs) for exploring the
connections between the specific genes. This plat-
form allows the user to interactively explore a sin-
gle feature’s association with other omics data and
customize its particular context (e.g. male/female
specific). The users can also register their data for
sharing and visualization of the MOBNs and GCNs.
Moreover, iNetModels allows users who do not have a
bioinformatics background to facilitate human well-
ness and disease research. iNetModels can be ac-




During the past decade, the development of high-
throughput technologies has dramatically decreased
the cost of generating large-scale multi-omics datasets (1).
This has opened up the possibilities to study human well-
ness and diseases systematically (2). Although analysis of
individual omics methodologies has been proven beneficial
in different clinical applications, integrating multi-omics
data may offer novel insights and provide a more com-
prehensive understanding of biological functions in the
human body in health and disease (3). For instance, a recent
study integrated time series phenomics, metabolomics and
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fluxomics data from the subjects with various degrees of
liver fat and revealed that non-alcoholic fatty liver disease
(NAFLD) is associated with glycine and serine deficiency
(4). Another longitudinal phenomics, transcriptomics,
metagenomics and metabolomics data have been generated
for 10 subjects during a two-week follow-up study. This
study has illustrated the rapid metabolic benefits of an
isocaloric carbohydrate-restricted diet on NAFLD patients
and revealed the molecular mechanisms associated with the
metabolic changes (5). Moreover, several other studies have
also demonstrated the benefit of performing longitudinal
multi-omics data analysis in systematically capturing
human diseases’ dynamics (6–8).
To provide a better framework for facilitating these types
of investigations, we created iNetModels. This user-friendly
platform provides exploratory capabilities and interactive
and intuitive visualization of clinical chemistry, anthropo-
metric parameters, plasma proteins, plasma metabolites,
oral microbiome and gut microbiome associated with the
user-queried features (Figure 1A). The data in iNetModels
are obtained from recent studies, where large-scale Multi-
Omics Biological Networks (MOBNs) analyses have been
performed for individuals with different metabolic condi-
tions. Moreover, we retrieved data from The Genotype-
Tissue Expression (GTEx) Project and The Cancer Genome
Atlas (TCGA), created normal tissue- and cancer-specific
Gene Co-expression Networks (GCNs) and presented the
networks in the iNetModels (Figure 1A). The user can si-
multaneously query for 1–5 features, visualize the selected
features and their neighbouring features, download the as-
sociated network in both table and figure format, and anal-
yse them using independent network analysis tools, includ-
ing Cytoscape (9) and iGraph (10). We also encourage users
to upload their networks into iNetModels and make those
networks accessible to a broader audience for creating an
open platform to share and visualize their networks. To our
knowledge, iNetModels is the first database that provides
associations between the multi-omics data obtained from
the same individuals in a physiological context rather than
using a text mining method.
PLATFORM DESCRIPTION AND FEATURES
iNetModels 2.0 is a web-based platform that includes two
main features: a database and an interactive visualization
of multi-omics network analysis (Figure 1B). It is an up-
dated and improved version of the previous work, TCSBN,
released in 2017 (11). First, we reconstructed the GCNs
presented in TCSBN based on more recent datasets and
expanded it to 85 different tissue- and cancer-specific net-
works. Second, we broadened the platform by adding 20
MOBNs from multiple independent studies. Finally, we im-
proved the backend and frontend of the platform for a
better user experience. To our knowledge, this platform is
the only publicly available platform that enables the explo-
ration of MOBNs that were generated based on personal-
ized omics data.
Data sources
The tissue- and cancer-specific GCNs were constructed us-
ing GTEx (v8) and TCGA (v27.0-fix) primary tumour data,
respectively. We retrieved the gene transcripts per million
(TPM) from GTEx Portal and the fragment per kilobase
of transcript per million mapped reads (FPKM) files of
the TCGA program from the Genomics Data Commons
(GDC) portal.
MOBNs were generated as the consensus of clini-
cal variables, plasma proteomics, plasma metabolomics
and metagenomics data based on from three indepen-
dent longitudinal wellness profiling studies: (i) SCAPIS-
SciLifeLab Wellness Profiling study (12): clinical variables,
metabolomics, proteomics and gut metagenomics data from
4 visits over a year from 101 individuals (50–65 years old),
(ii) P100 study (13): clinical variables, metabolomics and
proteomics data collected from three visits of 108 individ-
uals (21–89+ years old) in over 9 months, (iii) Integra-
tive Personal Omics (14): clinical variables, metabolomics
and proteomics data from three visits over weight gain
and loss period (97 days) from 10 insulin-sensitive (IS) and
13 insulin-resistance (IR) overweight individuals. More-
over, we generated MOBNs for two different clinical tri-
als where combined metabolic activators (CMA) admin-
istered to NAFLD and COVID-19 patients: (i) NAFLD
CMA administration: clinical variables, metabolomics, pro-
teomics and metagenomics data for the oral and gut micro-
biome of 31 NAFLD patients from three visits over 70 days,
and (ii) COVID-19 CMA administration: Clinical variables,
metabolomics and proteomics data collected 93 COVID-19
patients from two visits over 14 days.
Network generations
Each dataset was pre-processed independently before the
network generation. The gene expression data were filtered
to remove lowly expressed genes (TPM < 1 or FPKM < 1)
in each tissue or cancer type to avoid bias. For the multi-
omics data, we corrected them by removing the effects of
age (in all networks) and sex (in the non-gender-specific
networks) using trimmed mean robust regression (13). We
combined the data from each omics into a matrix to gener-
ate a network and analysed it using the Spearman correla-
tion function from the SciPy package. Each data source was
processed independently. After filtering for striking corre-
lations between the pairs, we filtered the pairs with FDR
<0.05. Furthermore, we performed community detection
analysis using the Leiden algorithm (15) in the iGraph pack-
age to identify sub-network clusters for downstream analy-
sis.
Moreover, in the longitudinal wellness profiling stud-
ies, we calculated both cross-sectional and delta networks.
These networks are generated based on the methodology
presented in the P100 wellness study (13). Cross-sectional
networks were calculated by correlating data from all vis-
its to represent correlations in the context of individual-
ized variation. Meanwhile, delta networks were calculated
by correlating the analyte changes between visits to allow
users to investigate features that co-vary within the same
time intervals.
The number of the nodes and edges in the generated net-
works varying between 5673 (liver cancer)––12 581 (testis)
nodes and 63 292 (endocervix)––132 223 286 (testis) edges
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Figure 1. (A) Summary of multi-omics data presented in iNetModels (B) Working page of iNetModels.
nodes and 1034 (Delta IS)––566 390 (SCAPIS––SciLifeLab
Longitudinal Male) edges in MOBNs (Supplementary Ta-
ble S1).
Features
The iNetModels platform provides users with a vast num-
ber of pre-computed biological networks. Users may choose
the suitable networks from tissue- or cancer-specific GCNs
to gender or IR/IS-specific MOBNs based on their study’s
focus. To search within a specific network (Figure 1B, Sup-
plementary Figure S1), firstly, users need to select the spe-
cific network category (GCNs or MOBNs), then select the
specific network type (normal tissue, cancer, or multi-omics
study), and subsequently select the specific network. Fol-
lowing that, users need to input the commonly known
names of analytes (gene, protein, metabolite name etc.) of
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Figure 2. (A) Validation of the hypothesis about the supplementation of L-Serine that was associated with the decrease in the plasma triglycerides levels
and liver enzyme (ALAT) in the SCAPIS-SciLifeLab Wellness Profiling study. (LINK). (B) The two main components of the supplementation (L-cysteine
and L-serine) and their neighbouring analytes are presented based on multi-omics biological networks analysis (LINK). (C) The two main components
of the supplementation (L-cysteine and L-serine) and their associations with the species in the gut microbiome are presented (LINK). All networks in this
figure were taken from the cross-sectional overall SCAPIS-SciLifeLab Wellness Profiling study.
users can filter the network based on the analyte types (in
multi-omics networks) and statistical properties, e.g. FDR
and Spearman correlation ranking (positive, negative, or
both correlations). In the web interface, the number of
neighbouring nodes is limited to a maximum of 50 neigh-
bours per-queried nodes to avoid browser unresponsive-
ness. Furthermore, in the ‘additional options’ box, users can
choose to include neighbours’ connections in the networks
and disable network visualization when only network tables
are needed.
Once the network is generated, the users can interac-
tively explore the network, download the network as a fig-
ure and its content in a table format for further exploration
and downstream analysis. All information about each an-
alyte (network nodes) and related associations (network











niversity of Technology user on 29 July 2021
Nucleic Acids Research, 2021, Vol. 49, Web Server issue W275
description, unit, correlation and the P-value of the sig-
nificant associations etc. Besides, wherever possible, ana-
lytes are linked with external databases such as KEGG (16),
Human Protein Atlas (17–19), Uniprot (20) and HMDB
(21) to facilitate further biological interpretation and in-
vestigation. All of this information can be downloaded
directly and is compatible with other network analysis
tools and software, such as Cytoscape or iGraph package
in Python and R. By using these tools, users can merge
multiple networks and perform additional downstream
analysis.
Moreover, in the iNetModels 2.0, we implemented pro-
grammatic access to the database using an in-house-built
Python package that can be found under the ‘API’ section.
With the API, users can retrieve more extensive networks
(>50 neighbours per-queried nodes) programmatically. We
currently limit the query to one query per second.
Case study related to administration of CMA in NAFLD
One of our platform’s unique features and superior
strengths is that iNetModels 2.0 is the first and only plat-
form supporting the exploration of MOBNs based on per-
sonalized data. This is a great advantage to avoid bias since
all data were analysed in a paired manner.
In our recent study (22), we tested a potential therapeu-
tic strategy for NAFLD patients through CMA adminis-
tration. We provided CMA to 10 subjects involved in the
trial and collected plasma samples during the day to gen-
erated proteomics and metabolomics data. The data gener-
ated in the clinical trial were analysed using metabolic mod-
elling. The results of the analysis were validated by perform-
ing animal experiments, where L-serine was supplemented
to mouse and a reduction in the liver triglycerides (TG)
and markers of liver tissue functions, e.g. ALAT, ASAT,
and ALP was observed. We validated these results in two
independent MOBNs in iNetModels 2.0 (Figure 2A, Sup-
plementary Figure S2A). Our analysis revealed that two
metabolic activators, including L-serine and L-cysteine are
positively associated with metabolites related to branched
amino-acid metabolism (i.e. L-valine, L-isoleucine and L-
leucine) and negatively associated with plasma glucose
level, supporting the main findings of the study (Figure 2B).
The MOBNs also showed that L-serine is associated nega-
tively with cholesterol-related clinical variables (ApoB, TG)
and several other inflammation markers (hsCRP, IL1RN
and CD300C).
Based on the same network, we can filter to show only
specific analyte types (Figure 2C, Supplementary Figure
S2B–D). For example, we used the same network to show
the association of L-cysteine and L-serine with only the gut
microbiome (Figure 2C), as dysbiosis in the gut microbiome
has been associated with NAFLD (23,24). We observed that
L-cysteine had a positive correlation with the abundance of
Lachnospiraceae and a negative correlation with the abun-
dance of the Enterococcaceae family. Independent studies
have shown that the abundance of Lachnospiraceae was in-
creased in cirrhosis (25,26), whereas the abundance of Ente-
rococcaceae was decreased in cirrhosis (25). We also found
that the levels of both L-serine and L-cysteine were nega-
tively correlated with the abundance of the Desulfovibri-
onaceae family, which was increased with the severity of
NAFLD (27).
CONCLUSION
iNetModels is a unique platform that gathers a broad
spectrum of biological networks, from tissue- and cancer-
specific GCNs to MOBNs based on personalized data. This
platform may help researchers to perform exploration and
validation experiments, identify functional relationships be-
tween the analytes, and most importantly, provide new in-
sights into the biological experiments and ultimately iden-
tify potential drug targets and biomarkers. The case study
about the supplementation of CMA in NAFLD patients
has shown the efficient usage of this platform in testing and
validating hypotheses as well as confirming results from ex-
periments or clinical trials. This platform is designed in a
user-friendly way and it is freely accessible to a wide range
of users, including bench scientists with limited or no for-
mal bioinformatics background. We also envisage that this
platform will be a key resource for computational biologists
working in omics data integration, network science, systems
biology and systems medicine. In this context, we expect
iNetModels to be an essential resource for more in-depth
multi-omics analysis that may reveal novel molecular mech-
anisms underlying human wellness and disease.
In the future, in addition to the inclusion of more stud-
ies, we are planning to expand the functionalities of the
platform. First, with the increasing number of personalized
wellness profiling study, we plan to develop a method to
build a consensus MOBN based on various studies to in-
crease the robustness of the findings generated from this
platform. Second, we plan to add a functional analysis fea-
ture to show the enriched pathways or biological processes
by integrating the selected network information to other
databases, such as KEGG (16) or Metabolic Atlas (28). Fi-
nally, we will add integration with users’ quantitative omics
data or statistical inference results to identify the signifi-
cantly altered nodes in various perturbations.
DATA AVAILABILITY
iNetModels can be accessed freely by everyone at https:
//inetmodels.com without any limitation. All codes used to
generate the network and the network data are available un-
der the ‘API’ and ‘Help’ section of the website.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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employees of Bash Biotech Inc., San Diego, CA, USA. The
other authors declare no conflict of interest.
REFERENCES
1. Goodwin,S., McPherson,J.D. and McCombie,W.R. (2016) Coming of
age: ten years of next-generation sequencing technologies. Nat. Rev.
Genet., 17, 333–351.
2. Karczewski,K.J. and Snyder,M.P. (2018) Integrative omics for health
and disease. Nat. Rev. Genet., 19, 299–310.
3. Hasin,Y., Seldin,M. and Lusis,A. (2017) Multi-omics approaches to
disease. Genome Biol., 18, 83.
4. Mardinoglu,A., Bjornson,E., Zhang,C., Klevstig,M., Soderlund,S.,
Stahlman,M., Adiels,M., Hakkarainen,A., Lundbom,N.,
Kilicarslan,M. et al. (2017) Personal model-assisted identification of
NAD(+) and glutathione metabolism as intervention target in
NAFLD. Mol. Syst. Biol., 13, 916.
5. Mardinoglu,A., Wu,H., Bjornson,E., Zhang,C., Hakkarainen,A.,
Rasanen,S.M., Lee,S., Mancina,R.M., Bergentall,M.,
Pietilainen,K.H. et al. (2018) An integrated understanding of the
rapid metabolic benefits of a carbohydrate-restricted diet on hepatic
steatosis in humans. Cell Metab., 27, 559–571.
6. Chen,R., Mias,G.I., Li-Pook-Than,J., Jiang,L., Lam,H.Y., Chen,R.,
Miriami,E., Karczewski,K.J., Hariharan,M., Dewey,F.E. et al. (2012)
Personal omics profiling reveals dynamic molecular and medical
phenotypes. Cell, 148, 1293–1307.
7. David,L.A., Materna,A.C., Friedman,J., Campos-Baptista,M.I.,
Blackburn,M.C., Perrotta,A., Erdman,S.E. and Alm,E.J. (2014) Host
lifestyle affects human microbiota on daily timescales. Genome Biol.,
15, R89.
8. Smarr,L. (2012) Quantifying your body: a how-to guide from a
systems biology perspective. Biotechnol. J., 7, 980–991.
9. Shannon,P., Markiel,A., Ozier,O., Baliga,N.S., Wang,J.T.,
Ramage,D., Amin,N., Schwikowski,B. and Ideker,T. (2003)
Cytoscape: a software environment for integrated models of
biomolecular interaction networks. Genome Res., 13, 2498–2504.
10. Csardi,G. and Nepusz,T. (2006) The igraph software package for
complex network research. InterJ. Complex Syst., 1695, 1–9.
11. Lee,S., Zhang,C., Arif,M., Liu,Z., Benfeitas,R., Bidkhori,G.,
Deshmukh,S., Al Shobky,M., Lovric,A., Boren,J. et al. (2018)
TCSBN: a database of tissue and cancer specific biological networks.
Nucleic Acids Res., 46, D595–D600.
12. Tebani,A., Gummesson,A., Zhong,W., Koistinen,I.S.,
Lakshmikanth,T., Olsson,L.M., Boulund,F., Neiman,M.,
Stenlund,H., Hellstrom,C. et al. (2020) Integration of molecular
profiles in a longitudinal wellness profiling cohort. Nat. Commun., 11,
4487.
13. Price,N.D., Magis,A.T., Earls,J.C., Glusman,G., Levy,R., Lausted,C.,
McDonald,D.T., Kusebauch,U., Moss,C.L., Zhou,Y. et al. (2017) A
wellness study of 108 individuals using personal, dense, dynamic data
clouds. Nat. Biotechnol., 35, 747–756.
14. Piening,B.D., Zhou,W., Contrepois,K., Rost,H., Gu Urban,G.J.,
Mishra,T., Hanson,B.M., Bautista,E.J., Leopold,S., Yeh,C.Y. et al.
(2018) Integrative personal omics profiles during periods of weight
gain and loss. Cell Syst., 6, 157–170.
15. Traag,V.A., Waltman,L. and van Eck,N.J. (2019) From Louvain to
Leiden: guaranteeing well-connected communities. Sci. Rep., 9, 5233.
16. Kanehisa,M., Furumichi,M., Tanabe,M., Sato,Y. and Morishima,K.
(2017) KEGG: new perspectives on genomes, pathways, diseases and
drugs. Nucleic Acids Res., 45, D353–D361.
17. Thul,P.J., Akesson,L., Wiking,M., Mahdessian,D., Geladaki,A., Ait
Blal,H., Alm,T., Asplund,A., Bjork,L., Breckels,L.M. et al. (2017) A
subcellular map of the human proteome. Science, 356, eaal3321.
18. Uhlen,M., Fagerberg,L., Hallstrom,B.M., Lindskog,C., Oksvold,P.,
Mardinoglu,A., Sivertsson,A., Kampf,C., Sjostedt,E., Asplund,A.
et al. (2015) Proteomics. Tissue-based map of the human proteome.
Science, 347, 1260419.
19. Uhlen,M., Zhang,C., Lee,S., Sjostedt,E., Fagerberg,L., Bidkhori,G.,
Benfeitas,R., Arif,M., Liu,Z., Edfors,F. et al. (2017) A pathology
atlas of the human cancer transcriptome. Science, 357, eaan2507.
20. The UniProt, C. (2017) UniProt: the universal protein
knowledgebase. Nucleic Acids Res., 45, D158–D169.
21. Wishart,D.S., Feunang,Y.D., Marcu,A., Guo,A.C., Liang,K.,
Vazquez-Fresno,R., Sajed,T., Johnson,D., Li,C., Karu,N. et al. (2018)
HMDB 4.0: the human metabolome database for 2018. Nucleic Acids
Res., 46, D608–D617.
22. Zhang,C., Bjornson,E., Arif,M., Tebani,A., Lovric,A., Benfeitas,R.,
Ozcan,M., Juszczak,K., Kim,W., Kim,J.T. et al. (2020) The acute
effect of metabolic cofactor supplementation: a potential therapeutic
strategy against non-alcoholic fatty liver disease. Mol. Syst. Biol., 16,
e9495.
23. Oh,T.G., Kim,S.M., Caussy,C., Fu,T., Guo,J., Bassirian,S., Singh,S.,
Madamba,E.V., Bettencourt,R., Richards,L. et al. (2020) A universal
gut-microbiome-derived signature predicts cirrhosis. Cell Metab., 32,
878–888.
24. Aron-Wisnewsky,J., Vigliotti,C., Witjes,J., Le,P., Holleboom,A.G.,
Verheij,J., Nieuwdorp,M. and Clement,K. (2020) Gut microbiota and
human NAFLD: disentangling microbial signatures from metabolic
disorders. Nat. Rev. Gastroenterol. Hepatol., 17, 279–297.
25. Bajaj,J.S., Heuman,D.M., Hylemon,P.B., Sanyal,A.J., White,M.B.,
Monteith,P., Noble,N.A., Unser,A.B., Daita,K., Fisher,A.R. et al.
(2014) Altered profile of human gut microbiome is associated with
cirrhosis and its complications. J. Hepatol., 60, 940–947.
26. Chen,Y., Yang,F., Lu,H., Wang,B., Chen,Y., Lei,D., Wang,Y., Zhu,B.
and Li,L. (2011) Characterization of fecal microbial communities in
patients with liver cirrhosis. Hepatology, 54, 562–572.
27. Zhang,X., Coker,O.O., Chu,E.S., Fu,K., Lau,H.C.H., Wang,Y.X.,
Chan,A.W.H., Wei,H., Yang,X., Sung,J.J.Y. et al. (2020) Dietary
cholesterol drives fatty liver-associated liver cancer by modulating gut
microbiota and metabolites. Gut, 70, 761–774.
28. Robinson,J.L., Kocabas,P., Wang,H., Cholley,P.E., Cook,D.,
Nilsson,A., Anton,M., Ferreira,R., Domenzain,I., Billa,V. et al.











niversity of Technology user on 29 July 2021
